Frontage Laboratories Acquires Teddy Lab
Frontage Laboratories, Inc. (“Frontage”), a leading global CRO/CDMO, today announced the completion of the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. (“Teddy Lab”), a leading...
Category : Clinical Research, Pharma & Healthcare Financing
NAMI Announces Appointment of Nathan Paul Romano to National Board
The National Alliance on Mental Illness (NAMI) today announced that Nathan Paul Romano has joined its national board of directors. Romano is a leading mental...
Droplet Biosciences Accelerates Residual Cancer Detection with NVIDIA
Droplet reduces genomic analysis time using NVIDIA Parabricks, enabling rapid turnaround of test results Droplet Biosciences, a diagnostics company pioneering lymph-based liquid biopsy testing, today announced that...
PureHealth Research Launches “Natural GLP-1 Support” Collection
PureHealth Research has launched its Natural GLP-1 Support collection, a line of natural GLP-1 supplements offering a needle-free, prescription-free alternative to synthetic injections that can cost thousands of dollars per year. The collection...
FDB Vela, Photon Expand ePrescribing Transparency
The integration with FDB Vela will broaden pharmacy connectivity and enhance prescription routing to support a more modern, patient-oriented prescribing experience FDB (First Databank, Inc.), the...
Neurogene’s NGN-401 Gets FDA Breakthrough Therapy Status
Breakthrough Therapy designation granted based on interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multidomain functional improvements for Neurogene’s lead program On track...
Kairos Pharma Signs Term Sheet for Two Oncology Assets
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma’s clinical portfolio to target multi-billion...
Argo Biopharma Shares Phase II Results for BW-20805 at AAAAI
-Poster Presentation Selected as Late Breaking Abstract- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected as...
CJ BIO Publishes Study on BiomeNrich POST SZ075 for Skin Health
CJ BIO announced the publication of clinical research findings on its postbiotic ingredient, BiomeNrich™ POST SZ075, in an international peer-reviewed journal. The study strengthens the...
Matricelf Reports 2025 Milestones, 2026 Spinal Implant Roadmap
Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies for spinal cord injury, today issued a shareholder update summarizing its 2025 achievements and...
FDA Grants Full Approval to Pfizer’s BRAFTOVI for Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed...
Mevion Medical CE Marks S250-FIT Proton Therapy System for Global Use
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems,...
Astellas & Vir Biotech Team on PRO-XTEN® VIR-5500 Cancer Drug
– Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues – – Astellas to lead commercialization of VIR-5500 in...
Frontier Biotech & GSK License siRNA Therapeutics Globally
Frontier Biotechnologies Inc. (hereinafter referred to as “Frontier Biotech” or “the Company”) has entered into an exclusive licensing agreement with GSK, a global biopharma company. Under the...
Virion Reports Phase 1b Anti-HBV Data at CROI 2026
Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI), in Denver, CO,...